BRAF and neoplasm: The analysis of clinical and molecular markers (below) showed that subtype C is enriched for MSI tumours and BRAF mutant tumours, the latter present also in subtype D. The literature indicates that MSI is associated with better RFS, while BRAF mutation is an indicator of worse SAR 27.